PGEN Stock Analysis

Precigen Inc
HEALTHCARE BIOTECHNOLOGY

Back to Winners View Yahoo Finance Chart Buy on the Dip
Strong Caution Mixed Weak Unavailable
StockValueFinder Grade
F
40.66 / 100
Weak
Confidence: High (84.0%) Coverage: 84.0%
Business Quality 5.5
Financial Strength 43.0
Earnings & Growth 50.5
Valuation 45.6
Market Strength 76.5
The grade combines Business Quality, Financial Strength, Earnings & Growth, Valuation, and Market Strength. Rating and Trend remain separate signals.
Rating AVOID
Avoid
The screening rules are warning against this setup.
Rating is the simple decision label from the screening rules.
Trend NEUTRAL / WATCH
Watch
The trend is interesting but needs confirmation.
Trend shows whether price action is helping or hurting the setup.
P/E Ratio -4.46
Not Meaningful
Negative or missing earnings make P/E hard to use.
P/E shows how much investors pay for each dollar of earnings.
ROIC -210.27%
Poor
Negative ROIC suggests capital is not being used profitably.
ROIC measures how efficiently capital turns into profit.
Debt Payback -1.04 yrs
Unavailable
Debt payback is unavailable or not meaningful.
Debt payback estimates how quickly debt could be covered.
Interest Coverage -27.57x
Poor
Negative coverage means earnings are not covering interest costs.
Interest coverage shows how easily earnings cover interest costs.
Price $6.19
Market Price
Price alone is not a buy or sell signal.
Price should be judged with valuation, quality, and trend.
Last updated: 2026-10-25 11:26:24

Performance Overview

Trailing adjusted-close returns as of 2026-07-23. Benchmark is SPY.

YTD Return

PGEN +32.54%
SPY +8.83%

1-Year Return

PGEN +233.73%
SPY +17.68%

3-Year Return

PGEN +313.43%
SPY +69.45%

5-Year Return

PGEN +2.40%
SPY +79.56%

Returns are calculated from adjusted close prices and may differ from broker or research-site totals depending on data source, dividend handling, benchmark choice, and latest available trading date.

Legacy Screening Checks

This page uses cached SQL data from the latest StockValueFinder scan, so it loads fast without hitting Alpha Vantage on every page view.

43%
EPS Strength
FAIL

Looks for positive and improving earnings per share.

ROIC 10%+
FAIL

Looks for strong return on invested capital.

Interest Coverage 6+
FAIL

Checks whether operating income comfortably covers interest expense.

Debt Payback ≤ 3 Years
PASS

Checks whether free cash flow could pay down long-term debt quickly.

P/E 15 or Less
PASS

Checks whether valuation is reasonable under the current rule set.

Moving Average Trend
NEUTRAL / WATCH

Uses 20-day, 50-day, and 200-day moving averages for entry timing context.

A high StockValueFinder score is a research signal, not a guarantee. Strong companies can still fall during recessions, sector downturns, valuation resets, or company-specific events. Always review the business, risks, SEC filings, valuation, and your personal investment goals before buying.

Cached Technical Data

Moving average values from the latest stored scan.

20-Day MA7.41
50-Day MA7.26
200-Day MA5.22
MA Score3

Latest Published Stock Research

Research generated: October 24, 2026

PGEN Stock Analysis: Why Precigen Inc Scored 43% in Stock Value Finder

Precigen Inc (PGEN): An Educational StockValueFinder Review

This article provides an in-depth analysis of Precigen Inc (PGEN) using metrics from StockValueFinder.com to help you understand the company's financial health and investment potential. We will break down each metric, explain its significance, and provide examples for context.

Overview of Precigen Inc (PGEN)

Precigen Inc is a biotechnology company operating in the healthcare sector, focusing on developing innovative therapies through advanced genetic engineering technologies. The StockValueFinder score for PGEN stands at 43%, with an overall rating of AVOID, indicating that based on its financial metrics and valuation criteria, it may not be an ideal investment candidate.

Why the StockValueFinder Score Matters

The StockValueFinder score is a composite metric that evaluates various aspects of a company's financial health. It considers factors such as earnings consistency, capital efficiency, debt management, profitability, and valuation discipline to provide an overall assessment. A lower score like 43% suggests that Precigen Inc has significant weaknesses in one or more critical areas.

EPS Strength and Consistency

Earnings per share (EPS) is a key indicator of a company's financial performance and stability. StockValueFinder evaluates whether the EPS is consistent over time, reflecting steady earnings growth or declines. For PGEN, the system recorded that it did not pass the EPS test, meaning there may be inconsistencies in its earnings history.

**Example:** A company with stable EPS growth year-over-year indicates a reliable business model and predictable revenue streams, which are attractive to investors. Conversely, erratic EPS results can signal underlying issues or market volatility affecting profitability.

ROIC and Capital Efficiency

Return on invested capital (ROIC) measures how effectively a company uses its capital to generate returns. A higher ROIC indicates better use of resources. Precigen Inc's ROIC is -210.27%, which StockValueFinder generally prefers to see at 10% or higher.

**Example:** If Company X has an ROIC of 15%, it means that for every dollar invested, the company generates $0.15 in profit, compared to a competitor with only a 4% ROIC, suggesting less efficient capital use and potentially lower profitability over time.

Interest Coverage and Financial Safety

Interest coverage ratio shows how easily a company can cover its interest expenses with earnings before interest and taxes (EBIT). StockValueFinder prefers this ratio to be at least 6 or higher. Precigen Inc did not pass the interest coverage test, indicating potential financial strain if interest rates rise.

**Example:** A company with an interest coverage of 8x is in a healthier position compared to one with only 2x coverage because it can more comfortably meet its debt obligations even during economic downturns.

Debt Payback and Balance Sheet Discipline

Debt payback period measures how long it would take for a company to repay all outstanding debts using current earnings before interest, taxes, depreciation, and amortization (EBITDA). Precigen Inc's debt payback is -1.04 years, which StockValueFinder prefers to see at 3 years or less.

**Example:** A shorter debt payback period like 1.5 years suggests the company can quickly reduce its leverage, whereas a longer period of 7 years indicates slower progress in reducing financial risk and potential higher interest costs over time.

P/E Ratio and Valuation Discipline

The price-to-earnings (P/E) ratio compares a stock's market value to its earnings per share. StockValueFinder prefers a P/E ratio of 15 or lower for disciplined valuation. Precigen Inc has a P/E ratio of -4.46, which passed the valuation test despite being negative.

**Example:** A company with a P/E of 8 is generally considered more value-oriented compared to one with a P/E of 40, assuming both have similar business quality and growth prospects.

Moving Average Trend and Entry Timing

The moving average trend signal helps identify potential entry points based on historical price patterns. Precigen Inc's moving average signal is NEUTRAL / WATCH, indicating neither strong buy nor sell signals but rather a need for further analysis before making an investment decision.

**Example:** A stock with a positive moving average trend might be entering an uptrend phase, while a negative trend could suggest a downtrend ahead. However, these trends should not be the sole basis for buying or selling decisions.

Overall Financial Strengths and Weaknesses

Precigen Inc's financial profile shows several areas of concern

**Weak EPS consistency** indicates potential earnings instability. - **Poor ROIC performance** suggests inefficient capital allocation. - **Low interest coverage** implies vulnerability to rising interest rates. - However, the company passed the debt payback test, indicating rapid debt reduction capability.

Risks and Limitations

Investing in biotechnology companies like Precigen Inc involves significant risks due to

High research and development costs - Regulatory hurdles for new drug approvals - Market volatility affecting valuation multiples

Additionally, relying solely on financial metrics may overlook qualitative factors such as management expertise, competitive positioning, and pipeline developments.

Educational Conclusion

Understanding financial metrics is crucial in evaluating potential investments. This review of Precigen Inc highlights the importance of considering multiple aspects like earnings consistency, capital efficiency, debt management, profitability, and valuation discipline when assessing a company's investment merit. While some companies may pass certain tests, it’s essential to recognize that no single metric guarantees future performance.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.


Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings

Research Attribution
Max Qwen II

Specializing in monetary economics, market incentives, and investment risk.

30-Day Trendline Analysis

Optional intraday chart with rising support, falling resistance, and multi-timeframe views.

Load detailed price structure only when needed. Downloads roughly 30 days of 5-minute candles, identifies swing points, then calculates validated support and resistance lines.
Scroll to Top